How Many GLP-1 Drugs Are There? A Comprehensive Overview

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The GLP-1 receptor agonist class includes more than 15 distinct medications across injectable and oral delivery systems, with options continuing to expand. Beyond well-known brands like Ozempic and Mounjaro, compounded versions and newer oral formulations provide additional pathways for patients and providers to explore.

Navigating GLP-1 options requires understanding how medications differ in mechanism, delivery, cost, and individual response patterns. PlexusDx supports precision-wellness approaches by helping patients evaluate their full range of choices with qualified provider guidance before initiating or adjusting treatment.

The Expanded GLP-1 Market: Injectable Medications

Injectable GLP-1 receptor agonists dominate the current market. FDA-approved brands include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), liraglutide (Saxenda), and exenatide (Byetta, Bydureon). Each has distinct dosing schedules, onset kinetics, and clinical profiles determined through regulatory approval pathways.

Compounded semaglutide and tirzepatide injections prepared by licensed 503A pharmacies represent another category. These are not FDA-approved medications but may offer cost advantages and accessibility for patients seeking options outside traditional brand channels. Provider oversight remains essential for any injectable therapy.

Oral GLP-1 Formulations: Mechanism and Clinical Context

Oral GLP-1 medications have emerged as a major treatment segment. FDA-approved oral semaglutide (Rybelsus) and oral tirzepatide (Zepbound) represent pharmaceutical innovations addressing patient preference for non-injectable therapy. Compounded oral versions from licensed pharmacies also exist, though bioavailability and dosing differ from branded products.

Medication Type	Delivery Method	Typical Dosing	Key Consideration
Semaglutide (branded)	Injection or oral tablet	Weekly or daily	Long track record; varies by formulation
Tirzepatide (branded)	Injection or oral tablet	Weekly or daily	Dual GIP/GLP-1 agonist; newer data profile
Dulaglutide	Injection weekly	0.75-1.5 mg/week	Longer half-life; fixed-dose pens
Compounded injectables	Semaglutide or tirzepatide	Customizable per provider	From licensed 503A pharmacies; variable cost

Dual Agonists and Emerging Classes

Tirzepatide represents a dual GIP/GLP-1 receptor agonist, combining two signaling pathways for potentially broader metabolic effects compared to GLP-1-only agents. Clinical trials suggest numerically higher weight and glucose outcomes, though individual response varies considerably. Newer dual compounds and triple agonists continue entering development pipelines.

Retatrutide (triple agonist targeting GIP, GLP-1, and glucagon receptors) has shown promise in clinical trials but remains under regulatory review. As the GLP-1 landscape expands, providers increasingly tailor medication selection based on individual patient profiles rather than assuming all agents perform identically across populations.

Access, Cost, and Provider Guidance: Who Should Consider What

Brand-name GLP-1 medications offer established safety data, consistent formulations, and insurance coverage pathways, though costs remain high for uninsured patients. Compounded GLP-1 options from licensed 503A pharmacies may provide lower out-of-pocket costs starting around $149/mo monthly, depending on medication and formulation. Cost alone should never drive medication selection without provider input.

Initiation of any GLP-1 therapy requires medical evaluation, contraindication screening, and baseline metabolic assessment. Patients with personal or family history of medullary thyroid cancer, multiple endocrine neoplasia, or severe pancreatitis should not receive GLP-1 agonists. Pregnancy status, kidney function, and concurrent medications must be reviewed before starting treatment.

How PlexusDx Supports a More Personalized Approach

The Precision Peptide Genetic Test may help provide context for how an individual's biology relates to GLP-1 receptor and metabolic pathways. Variants in GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609) can support a more personalized conversation with a provider about which medication class or formulation might align with a patient's genetic predispositions in peptide-signaling pathways.

Genetic predispositions revealed by the Precision Peptide test should be interpreted with a qualified healthcare provider. The test identifies genetic variants associated with peptide pathway function but does not predict exact medication response or guarantee outcomes. It serves as one data point among clinical history, metabolic markers, and medical evaluation.

Understanding that multiple GLP-1 options exist—from brand-name injectables to compounded preparations—allows patients and providers to make informed decisions together. Genetic insights about peptide pathway predispositions may help support that conversation, ensuring treatment selection reflects both clinical evidence and individual biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How many FDA-approved GLP-1 drugs are currently available?

More than a dozen FDA-approved GLP-1 receptor agonists exist, including semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide in various formulations. Newer agents and dual/triple agonists continue entering the regulatory pipeline.

What is the difference between brand-name and compounded GLP-1 medications?

Brand-name GLP-1 drugs undergo FDA approval with standardized manufacturing and documented safety profiles. Compounded GLP-1 medications from licensed 503A pharmacies are prepared to prescription specifications but are not FDA-approved formulations. Both require provider oversight.

What GLP-1 options does PlexusDx offer?

PlexusDx provides compounded semaglutide injection ($149/mo), oral semaglutide ($249/mo), tirzepatide injection ($249/mo), oral tirzepatide ($279/mo), and GLP-Squared dual compound ($249/mo) from licensed 503A pharmacies. Microdose GLP-1 Protocol starts at $129/mo.

Are there safety concerns with choosing one GLP-1 over another?

All GLP-1 agonists carry similar contraindications: no use in personal/family history of medullary thyroid cancer, multiple endocrine neoplasia, or severe pancreatitis. Nausea, vomiting, and gastrointestinal side effects are common. Individual tolerability varies; provider monitoring ensures safe dosing.

How might genetic testing help inform GLP-1 medication choice?

The Precision Peptide Genetic Test identifies predispositions in GLP1R, GIPR, and metabolic pathways that may provide context for how an individual's biology relates to GLP-1 response. These insights should support a conversation with a provider but do not predict exact medication response.